Clinical, genomic, and neurophysiological correlates of lifetime suicide attempts among individuals with alcohol dependence

Peter B. Barr [1,2,3,4], Zoe Neale [1,2,3], Jessica Schulman [5], Niamh Mullins [6,7,8], Jian Zhang [1], David B. Chorlian [1], Chella Kamarajan [1], Sivan Kinreich [1], Ashwini K. Pandey [1], Gayathri Pandey [1], Stacey Saenz de Viteri [9], Laura Acion [10], Lance Bauer [11], Kathleen K. Bucholz [12], Grace Chan [10,11], Michael Chao [6], Danielle M. Dick [13,14], Howard J. Edenberg [15,16], Tatiana Foroud [15,17], Alison Goate [6], Victor Hesselbrock [11], Emma C. Johnson [12], John Kramer [10], Dongbing Lai [15], Martin H. Plawecki [17], Jessica E. Salvatore [13], Leah Wetherill [15], Arpana Agrawal [12], Bernice Porjesz [1], & Jacquelyn L. Meyers [1,2,3,4]

1. Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY
2. VA New York Harbor Healthcare System, Brooklyn, NY
3. Institute for Genomics in Health (IGH), SUNY Downstate Health Sciences University, Brooklyn, NY
4. Department of Epidemiology and Biostatistics, School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY
5. Multiple Myeloma Research Foundation, Norwalk, CT
6. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
7. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY
8. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
9. School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY
10. Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA
11. Department of Psychiatry, School of Medicine, University of Connecticut, Farmington, CT
12. Department of Psychiatry, School of Medicine, Washington University in St. Louis, St Louis, MO
13. Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ
14. Rutgers Addiction Research Center, Rutgers University, Piscataway, NJ
15. Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis, IN
16. Department of Biochemistry and Molecular Biology, School of Medicine, Indiana University, Indianapolis, IN
17. Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN

Corresponding author: Peter B. Barr
Department of Psychiatry and Behavioral Sciences
SUNY Downstate Health Sciences University
450 Clarkson Ave, MSC 1203, Brooklyn, NY 11203
e-mail: peter.barr@downstate.edu.

Abstract

Research has identified clinical, genomic, and neurophysiological markers associated with suicide attempts (SA) among individuals with psychiatric illness. However, there is limited research among those with an alcohol use disorder, despite their disproportionately higher rates of SA. We examined lifetime SA in 4,068 individuals with DSM-IV alcohol dependence from the Collaborative Study on the Genetics of Alcoholism (23% lifetime suicide attempt; 53% female; 17% Admixed African American ancestries; mean age: 38). We 1) explored clinical risk factors associated with SA, 2) conducted a genome-wide association study of SA, 3) examined whether individuals with a SA had elevated polygenic scores for comorbid psychiatric conditions (e.g., alcohol use disorders, lifetime suicide attempt, and depression), and 4) explored differences in electroencephalogram neural functional connectivity between those with and without a SA. One gene-based finding emerged, *RFX3* (Regulatory Factor X, located on 9p24.2) which had supporting evidence in prior research of SA among individuals with major depression. Only the polygenic score for suicide attempts was associated with reporting a suicide attempt (OR = 1.20, 95% CI = 1.06, 1.37). Lastly, we observed decreased right hemispheric frontal-parietal theta and decreased interhemispheric temporal-parietal alpha electroencephalogram resting-state coherences among those participants who reported a SA relative to those who did not, but differences were small. Overall, individuals with alcohol dependence who report SA appear to experience a variety of severe comorbidities and elevated polygenic risk for SA. Our results demonstrate the need to further investigate suicide attempts in the presence of substance use disorders.

Introduction

Approximately 2-5% of U.S. adults report having attempted suicide in their lifetimes [1–3], with the prevalence increasing in more recent birth cohorts [4]. Additionally, deaths by suicide are one of the leading causes in the recent decline in U.S. life expectancy, alongside other "deaths of despair" such as drug and alcohol related deaths [5, 6]. While the rate of suicide attempts in the general population is alarming, the rate of lifetime suicide attempts is greater than triple (17.5%) among those with an alcohol use disorder (AUD) [7]. Among those seeking treatment for AUD, 40% report at least one suicide attempt at some point in their lives [8–11]. Since a history of past suicide attempts is among the most prominent risk factors leading to subsequent suicide death and contributes significant health care and disability costs per attempt [12], research focused on correlates of suicide attempts can potentially help identify and treat those with non-fatal suicide attempts, with the goal of reducing suicide deaths and saving lives [13]. These data point to those with AUD as a particularly high-risk group.

Recent genome-wide association studies (GWAS) have identified genomic markers associated with suicide attempts (SA) broadly [14] and among individuals with psychiatric illness [15, 16]. The International Suicide Genetics Consortium (now the Suicide Working Group of the Psychiatric Genomics Consortium, or PGC) identified an intergenic locus on chromosome 7 (rs62474683) associated with SA in a large-scale meta-analysis of ~30,000 SA cases and >500,000 controls and replicated the association in an independent sample from Department of Veterans Affairs Million Veteran Program [14, 17]. Importantly, the SNP on chromosome 7 remained significant after conditioning on GWAS results for depression [15]. Other GWAS have identified genome-wide significant variants for SA within those with other psychiatric disorders: rs45593736 was associated with suicide attempt in major depressive disorder, chr4_23273116_D was associated with SA in bipolar disorder, and rs138689899 was associated in the meta-analysis of suicide attempt in mood disorders (bipolar disorder + major depressive disorder). However,

none of those findings replicated. Levey et al [16] found one genome-wide significant signal near *LDHB* (rs1677091) in individuals of European ancestries and three associations among individuals of African ancestries, including: rs683813 (*ARNTL2*), rs72740082 (*FAH*), and rs11876255. Variants within *LDHB* and *FAH* replicated in an independent sample.

In a parallel literature, GWAS have identified genomic markers associated with AUD and similar phenotypes [18–20]. For AUD, a recent GWAS from the Million Veteran Program (MVP) [19] identified three loci previously associated with alcohol dependence [20] —*ADH1B, ADH1C*, and *ADH4*, and seven novel loci -- *GCKR, SIX3, SLC39A8, DRD2*, an intergenic variant on chr10q25.1 (rs7906104), and *FTO*. A meta-analysis of AUD between MVP, PGC and the Collaborative Study on the Genetics of Alcoholism (COGA), which included 48,545 AUD cases and 187,065 controls, identified 10 genome-wide significant loci. In terms of AUD-adjacent phenotypes, Sanchez-Roige et al. (2019) meta-analyzed GWAS of the alcohol use disorders identification test (AUDIT) in 141,932 individuals from the UK Biobank and 23andme [18]; replicating previously identified signals in the genes *ADH1B, ADH1C, KLB*, and *GCKR* and finding novel associations localized to genes including *JCAD* and *SLC39A13*. Zhou et al [21] identified 29 independent risk variants, 19 of them novel, in. GWAS of "problematic alcohol use," meta-analyzing results from MVP, UK Biobank, and PGC. However, despite the higher rates of suicide attempts, no prior GWAS has examined suicide attempt in the presence of AUD.

Two separate literatures have explored neurocognitive differences between (a) individuals who have attempted suicide to those who have not [22–24] and (b) individuals with AUD [25–27] compared to those unaffected with AUD. Those with AUD have deficits in many domains of brain functioning including neuropsychological performance, and neurophysiological indices [25–27]. Executive functioning is the primary focus of such studies, with a large literature demonstrating that individuals with AUD display poorer executive functioning and atypical neurophysiological profiles (e.g., EEG connectivity) than individuals without AUD [28–31]. While these areas of brain

functioning have also been examined among individuals who have exhibited suicidal ideation and related mental health problems (depression) [22–24], research focused on SA is limited.

While no previous studies have examined EEG connectivity and SA, Leuchter et al. [32] examined EEG connectivity in depressed patients and found evidence of higher alpha and theta coherences in frontal, temporal, and parietal regions, and higher beta coherence in frontal and temporal regions. Further, a recent study found other neurophysiological differences associated with binge drinking and suicidal behaviors in Mexican American and American Indian adolescents [33]. To our knowledge, no prior study has examined neural connectivity among those with AUD who have attempted suicide.

Given the higher rates of SA observed among those with AUD, we explored whether there are clinical, genomic, and neurophysiological markers of SA within this population. Among participants diagnosed with DSM-IV Alcohol Dependence (AD) drawn from the Collaborative Study on the Genetics of Alcoholism (COGA), we: 1) compared clinical and other risk factors between those who have and have not reported a SA, 2) conducted a genome-wide association study (GWAS) of SA, 3) examined whether polygenic scores (PGS) for comorbid psychiatric problems were associated with SA, and 4) examined neurocognitive functioning among these individuals, given prior evidence of differences in brain function observed among individuals with psychiatric conditions who have a SA.

Methods

Sample and Measures

The Collaborative Study on the Genetics of Alcoholism (COGA) is a large, multi-site study of 17,854 participants from 2,255 families affected with AUD, designed to identify and understand genetic factors involved in the predisposition to alcoholism and related disorders, as previously described [34–36]. Participants 18 or older completed the Semi-Structured Assessment for the

Genetics of Alcoholism (SSAGA) which is a poly-diagnostic interview [34], and participants ages 12-17 completed an adolescent SSAGA. All participants were queried about whether they had "ever tried to kill" themselves (*suicide attempt*), regardless of a history of suicidal ideation (i.e., thoughts about killing yourself). Importantly, suicide attempt items were not exclusively nested within the diagnostic section for major depressive disorder (MDD), although individuals who reported suicide attempts in that section were coded accordingly as having reported the behavior.

Suicide attempt (SA) data derived from the SSAGA was available on 4,068 COGA participants with an alcohol dependence diagnosis (lifetime) and GWAS data (including 3,270 individuals of European ancestries and 798 individuals of African ancestries). For the current analyses, we included individuals reporting any suicide attempt, including those reporting drug-related suicide attempt (14% of all attempts). We created diagnoses of alcohol dependence, other substance dependence, other psychiatric disorders, suicidal thoughts and behaviors, and trauma exposure based upon DSM-IV criteria using the child and adult versions of the SSAGA. We assessed nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) scores [35]. Additionally, we included measures of sociodemographic characteristics, extended family histories of AD, and other alcohol-related problems (see supplementary information for a full description).

GWAS data

Genotyping, imputation and quality control have been described previously [36]. Briefly, genetic data were used to assign ancestry and families were classified as primarily European (EUR) or Admixed African American (AFR) ancestries according to the ancestry of the greatest proportion of family members [36]. Genotyping of 798 AFR individuals and 3270 EUR individuals included in the analytic sample was performed using the Illumina 2.5M array (Illumina, San Diego, CA, USA), the Illumina OmniExpress [37], the Illumina 1M array, or the Affymetrix Smokescreen array [38]. SNPs with a genotyping rate <98%, Hardy-Weinberg equilibrium violations ($p<10^{-6}$), or

with minor allele frequency (MAF) less than 3% were excluded from analyses. Mendelian inconsistencies were removed, after which data were imputed to 1000 genomes (Phase 3) using SHAPEIT [39] and IMPUTE2 [40]. Following imputation, dosage probabilities ≥ 0.90 were converted to hard calls. Mendelian errors in the imputed SNPs were reviewed and resolved as described previously [41, 42]. SNPs with an imputation information score < 0.30 or MAF < 0.03 were excluded from subsequent analysis.

Polygenic scores (PGS)

We estimated polygenic scores (PGS), which are aggregate measures of the number of risk alleles individuals carry weighted by effect sizes from GWAS summary statistics, using recent GWAS of (1) alcohol use disorders (AUD) [21], (2) depression (DEP, 23andMe excluded) [43], and (3) suicide attempt (SUI) [14]. To date, GWAS have been overwhelmingly limited to individuals of European ancestries [44]. Because of variation in allele frequencies and LD patterns, PGS often lose predictive accuracy when there is mismatch between the ancestries of the discovery GWAS and target sample [45, 46]. Because COGA includes participants of both African and European ancestries, we used PRS-CSx [47], a method that integrates GWAS summary statistics from well-powered GWAS (typically of European ancestries) with those from other populations to improve the predictive power of PGS in the participants of African ancestries in COGA. PRS-CSx employs a Bayesian approach to correct GWAS summary statistics for the non-independence of SNPs in linkage disequilibrium (LD). We converted PGS into Z-scores for ease of interpretation.

Electroencephalogram (EEG) data

EEG recording and processing have been detailed previously [48]. Briefly, resting (eyes-closed) EEG was recorded for 4.25 min; a continuous interval of 256 seconds was analyzed. Each subject wore a fitted electrode cap using the 61-channel montage as specified according to the

extended 10–20 International system. The nose served as reference and the ground electrode was placed on the forehead. Electrode impedances were always maintained below 5 kΩ. EEG was recorded with subjects seated comfortably in a dimly lit sound-attenuated temperature-regulated booth. They were instructed to keep their eyes closed and remain relaxed, but not to fall asleep. Electrical activity was amplified 10,000 times by Neuroscan and Masscomp amplifiers, with a bandpass between 0.02 Hz to 100 Hz and recorded using the Neuroscan system (Compumedics Limited; El Paso, TX). EEG procedures were identical at all COGA collection sites. Bipolar electrode pairs were derived to reduce volume conduction effects, and 27 representative coherence pairs were selected based on previous EEG coherence work in COGA [48]. Magnitude squared coherence was calculated from power spectral values derived from Fourier Conventional Fourier transform methods [49]. Coherence measures were generated between bipolar pairs at the following frequency bands: theta (3-7 Hz), alpha (7-12 Hz), beta (12-28 Hz).

Statistical analysis

We compared those with AD who reported a suicide attempt and those with AD who did not report a suicide attempt across a range of sociodemographic, clinical, and other measures. Multiple-group, multi-level regression models were conducted in Mplus [50] and adjusted for sex, age (at time of psychiatric assessment), ancestry, family history of AD, and family relatedness. We ran all models simultaneously (i.e., correlation among all variables accounted for) accounting for multiple testing.

We conducted GWAS, on 7,784,968 SNPs in the EUR sample and 16,100,604 SNPs in the AFR sample using a mixed model incorporating a genetic relationship matrix to control for relatedness [51] in the *GWAF* package in R [52]. We included sex, age, the first three ancestral PCs (PC1-PC3), genotype array, and birth cohort (prior to 1930, 1930-1949, 1950-1969, and 1970 and after) as covariates. GWAS were stratified by ancestries, using identical phenotypic definitions, covariates, SNP QC standards, MAF thresholds and imputation protocols.

Subsequently, we meta-analyzed across the AFR and EUR results using inverse-variance fixed-effects weighting and genomic control in METAL [53]. We used established thresholds for genome wide significance (p< 5 x 10^-8). Given that 56% of those with AD and suicide attempts also meet criteria for major depressive disorder, we also conducted a post-hoc GWAS analysis covarying for depression.

We performed gene-based tests using MAGMA [54] using FUMA v1.3.5 (Functional Mapping and Annotation of Genome-Wide Association Studies) [55] with 1000 genomes, phase 3 reference panel. Gene-based tests were performed for 12,337 genes (Bonferroni-corrected P value threshold = 4.05×10^{-6}) in EUR ancestries and 15,082 genes (Bonferroni-corrected P value threshold = $< 3.31 \times 10^{-6}$) in AFR ancestries. We sought converging evidence in the PGC GWAS of lifetime suicide attempts [15] among those with major depression, schizophrenia and bipolar disorder.

For polygenic scores, we ran two sets of comparisons. First, we compared those with AD who had reported a suicide attempt to those with AD who had not reported a suicide attempt across AUD, DEP, and SUI PGSs using logistic regression in R (version 4.2.1). Second, to ensure that results within those with AD were not biased by conditioning on AD [56], we also compared those with AD who had and had not reported a suicide attempt to those who have reported neither a suicide attempt nor meet criteria for AD (see Supplemental Table 1 for sample description) using a multinomial logistic regression model in the *nnet* package in R [57]. In both analyses, we included sex, age, the first three ancestral PCs (PC1-PC3), genotype array, and birth cohort as covariates. To adjust for familial clustering, we used cluster robust standard errors [58, 59].

Lastly, we compared those with AD who reported a suicide attempt and those with AD who did not report a suicide attempt across neurophysiological measures (resting state EEG coherence) using multiple-group, multi-level regression models were in Mplus. We included covariates for sex, age (at time of assessment), ancestry, family history of AD, and family relatedness.

Results

Clinical Risk Factors Associated with Suicide Attempt in Participants with AD

The main analytic sample was limited to the 4,068 participants with a DSM-IV diagnoses of alcohol dependence (AD). We compared 3,138 COGA participants who met criteria for DSM-IV AD and did not attempt suicide in their lifetime with 930 participants with AD who attempted suicide. Overall, those with AD who attempted suicide were more likely to be female (53% vs. 32%). Rates of suicide attempt and the age distribution of participants were similar across ancestry groups (see Supplemental Table 2 for ancestry stratified results). Table 1 presents the full set of comparisons across groups. The majority (58.4%) of the analytic sample endorsed suicidal ideation at some point in their lifetime; of those who attempted suicide, 97.6% endorsed prior suicidal ideation compared to 46.8% of those who did not attempt suicide. Participants with AD who had attempted suicide were more likely to have been exposed to traumatic events in their life, and to meet lifetime criteria for major depressive disorder, post-traumatic stress disorder, and other drug use disorders compared to those who had not attempted suicide. In addition, participants with AD that reported attempting suicide had higher family history densities of AD [60], started drinking at an earlier age, and had more severe indicators of alcohol-related problems.

Genomic Findings

Within the analytic sample we performed a GWAS of SA in those with available genetic data (no SA = 2,495 EUR and 643 AFR; SA = 775 EUR and 155 AFR). While there was no individual SNP associated with suicide attempts that reached genome-wide significance (see supplemental information for full results), Regulatory Factor X (*RFX3)* located on 9p24.2 was associated with suicide attempts among AD participants of European ancestry in gene-based analyses (Figure 1A). Similarly, *MPC2* (Mitochondrial Pyruvate Carrier 2, located on 1q24.2) was

associated with suicide attempts among AD participants of African ancestry in gene-based analyses (Figure 1B). Notably, several individual *RFX3* variants implicated in the European ancestry SNP-based GWAS just missed the threshold for genome-wide significance (Supplemental Figure 1B). We explored converging evidence in the PGC GWAS of suicide attempts conducted among those with psychiatric diagnoses (major depression, schizophrenia and bipolar Disorder) [15]. There was marginal evidence of a gene-based signal for *RFX3* in the analysis of suicide attempt within major depression (Supplemental Figure 2), but not schizophrenia or bipolar disorder. Additionally, when we covaried for depression in the GWAS of suicide attempts, the gene-based association of *RFX3* was no longer significant at the genome-wide level. There was no evidence supporting *MPC2*.

When we compared PGS for AUD, DEP, and SUI across persons with AD who had and had not attempted suicide (Figure 2, Panel A), neither PGS for AUD (OR_{EUR} = 1.04, 95% CI = 0.93, 1.16; OR_{AFR} = 1.15, 95% CI = 0.92, 1.42) nor DEP (OR_{EUR} = 1.04, 95% CI = 0.93, 1.17; OR_{AFR} = 0.99, 95% CI = 0.76, 1.28) was associated with increased odds of reporting suicide attempt. However, there was a positive association between the SUI PGS with odds of reporting suicide attempt but only in persons of European ancestries (OR_{EUR} = 1.20, 95% CI = 1.06, 1.37; OR_{AFR} = 1.36, 95% CI = 0.74, 1.42). Figure 2 (Panel B) shows results from the multinomial logistic models comparing those with AD who had (AD+, SA+) and had not (AD+, SA-) attempted suicide to those without an AD diagnosis and who had not attempted suicide. Relative to those without AD and no history of SA, the AUD PGS was associated with increased odds of both AD with no history of SA (OR_{EUR} = 1.31, 95% CI = 1.21, 1.41) and AD with a history of SA (OR_{EUR} = 1.40, 95% CI = 1.25, 1.56), but only in EUR ancestries. The DEP PGS was not associated with increased odds for any category, regardless of ancestry. Lastly, the SUI PGS was associated with increased odds of meeting the criteria for AD and having a history of suicide attempt (OR_{EUR} = 1.31, 95% CI = 1.16, 1.48), but again only in EUR ancestries (full results for PGS models presented in Supplemental Tables 3 and 4).

Neurophysiological Findings

We observed nominal differences in resting state EEG coherence patterns of alcohol dependent individuals who had attempted suicide compared to those who had not attempted suicide. However, only two findings withstood multiple test correction: decreased right hemispheric frontal-parietal theta (3-7Hz @ F8-F4--P8-P4) and decreased interhemispheric temporal-parietal alpha (7-12 Hz @ T8-P8--T7-P7) EEG resting-state coherences (p<0.001, Supplemental Figure 3). Exploratory analyses within a subset of individuals who had available neurocognitive measures is available in the supplementary information.

Discussion

Research has begun to identify clinical, genomic, and neurophysiological markers associated with suicide attempts among individuals with and without psychiatric illnesses (i.e., schizophrenia, bipolar disorder, depression) [13,14,15,16]. However, this has yet to be examined among those with AUD despite the higher rates of suicide attempts observed among those with AUD. The current study demonstrated clinical, genomic, and neurophysiological differences among individuals with AD who have attempted suicide when compared to individuals with AD who have not attempted suicide.

All participants with AD had elevated levels of suicidal ideation, other substance use disorders, and trauma exposure compared to the general population [2, 61]. However, among those who met criteria for AD and reported suicide attempts had even greater levels of all types of traumas (sexual, assaultive, and non-assaultive), other substance use disorders, suicidal ideation, and comorbid psychiatric conditions (PTSD and major depressive disorder) relative to those who had not attempted suicide.

In terms of genomic findings, *RFX3* (Regulatory Factor X, located on 9p24.2) was associated with SA at the gene level among those of European ancestries. *RFX3* is a transcription factor involved in development of brain white matter tracts, including corpus callosum and

thalamocortical tract [62–64]. *RFX3* has previously been implicated in GWAS of sleep [64, 65], depression [66, 67] and smoking [68, 69] related phenotypes. An intronic *RFX3* variant was identified as an RNA editing site identified in the brains of individuals with depression that died by suicide [69]. *RFX3* was identified in the GTEx database as an eQTL for *CARM1P1*, a nearby gene on chromosome 9 that is associated with depression in several large GWAS [70, 71]. Taken together, these data suggest that *RFX3,* or functionally related genes, may be a plausible risk locus for suicide attempts among those with AD and other psychiatric problems. Alternatively, *RFX3* may indeed be a risk locus for depression that we are detecting in our study, given that 56% of those with AD and suicide attempts also meet criteria for major depression and post-hoc analyses where we covaried for depression reduced the association below genome-wide significance. While the signal for *RFX3* is partially related to depression, there is some variance specific to suicide attempts. *MPC2* (Mitochondrial Pyruvate Carrier 2, located on 1q24.2) was associated with suicide attempts in those of African ancestry. *MPC2* variants have previously been implicated in genetic analyses of depression [72] and schizophrenia [73], but these analyses were limited to a relatively small number of participants. There was no evidence for a role of this gene in the PGC GWAS of suicide attempt. Future studies with greater ancestral diversity are needed to determine whether these genes are truly associated with SA.

When we examined the association between polygenic scores for alcohol use disorders, depression, and suicide attempt (SUI) with lifetime suicide attempt in persons with AD, only the PGS for suicide attempt was associated with a lifetime attempt, and this association was only significant in those of European ancestries. The lack of association of the SUI PGS in those of African ancestries likely stems from the small sample size of the discovery GWAS [74]. Importantly, in the multinomial logistic regression models, those with AD did not differ in mean levels of AUD PGS regardless of whether they had reported a lifetime suicide attempt. Similar to the logistic regression models limited to persons with AD, only the SUI PGS differentiated those who had attempted suicide from those who had not.

We also observed significant decreases in right hemispheric frontal-parietal theta (3-7 Hz @ F8-F4--P8-P4) and interhemispheric temporal-parietal alpha (7-12 Hz @ T8-P8--T7-P7) EEG resting-state coherences in the resting state among AD individuals who had attempted suicide. While there are no prior studies of suicide attempt that examined EEG coherence, differences in alpha and theta coherences in frontal, temporal, and parietal regions, and higher beta coherence in frontal and temporal regions were found previously in depressed patients [75]. Together, these data suggest that while both decreased theta and alpha resting state connectivity are likely among AD individuals with depression and suicide attempts, but more data are needed to make definitive any conclusions.

We also note several important limitations. We note that suicide rates have changed significantly over the past several decades, partially spanning the interval of data collection. Additional research is needed in the area of suicide attempts among individuals with substance use disorders and other psychiatric comorbidities. While this study focused on AD, there is also a high rate of suicide attempts among individuals with other substance use disorders, particularly cocaine and opioid use disorders. Additionally, we do not have data on those who completed suicide, which may differ from those who have attempted but not completed. Lastly, larger and more diverse samples are needed so that the benefits of this research can benefit all segments of the population [76].

Research is beginning to identify risk factors for suicidal behaviors. In the current analysis, we demonstrated that *RFX3,* polygenic scores for suicide attempt, and lower neurophysiological functioning were associated with suicide attempts among individuals with AD. Future work with larger and more diverse samples can examine additional risk factors, such as social and environmental conditions. Identifying robust predictive markers within an already high risk group may allow for earlier intervention and prevention from unnecessary loss of human life.

Acknowledgements

Research reported in this publication was supported by the National Institute on Alcohol Abuse and Alcoholism and the National Institute of Drug Abuse of the National Institutes of Health under award numbers. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research also used summary data from the Psychiatric Genomics Consortium (PGC), the Million Veterans Program (MVP), and the International Suicide Genetics Consortium (ISGC, now part of the PGC). We would like to thank the many studies that made these consortia possible, the researchers involved, and the participants in those studies, without whom this effort would not be possible.

The Collaborative Study on the Genetics of Alcoholism (COGA), Principal Investigators B. Porjesz, V. Hesselbrock, T. Foroud; Scientific Director, A. Agrawal; Translational Director, D. Dick, includes ten different centers: University of Connecticut (V. Hesselbrock); Indiana University (H.J. Edenberg, T. Foroud, Y. Liu, M.H. Plawecki); University of Iowa Carver College of Medicine (S. Kuperman, J. Kramer); SUNY Downstate Health Sciences University (B. Porjesz, J. Meyers, C. Kamarajan, A. Pandey); Washington University in St. Louis (L. Bierut, J. Rice, K. Bucholz, A. Agrawal); University of California at San Diego (M. Schuckit); Rutgers University (J. Tischfield, D. Dick, R. Hart, J. Salvatore); The Children's Hospital of Philadelphia, University of Pennsylvania (L. Almasy); Icahn School of Medicine at Mount Sinai (A. Goate, P. Slesinger); and Howard University (D. Scott). Other COGA collaborators include: L. Bauer (University of Connecticut); J. Nurnberger Jr., L. Wetherill, X., Xuei, D. Lai, S. O'Connor, (Indiana University); G. Chan (University of Iowa; University of Connecticut); D.B. Chorlian, J. Zhang, P. Barr, S. Kinreich, G. Pandey (SUNY Downstate); N. Mullins (Icahn School of Medicine at Mount Sinai); A. Anokhin, S. Hartz, E. Johnson, V. McCutcheon, S. Saccone (Washington University); J. Moore, F. Aliev, Z. Pang, S. Kuo (Rutgers University); A. Merikangas (The Children's Hospital of Philadelphia and University of Pennsylvania); H. Chin and A. Parsian are the NIAAA Staff Collaborators. We

continue to be inspired by our memories of Henri Begleiter and Theodore Reich, founding PI and Co-PI of COGA, and also owe a debt of gratitude to other past organizers of COGA, including Ting-Kai Li, P. Michael Conneally, Raymond Crowe, and Wendy Reich, for their critical contributions. This national collaborative study is supported by NIH Grant U10AA008401 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA).

References

1. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry. 1999;56:617–626.

2. Baca-Garcia E, Perez-Rodriguez MM, Keyes KM, Oquendo MA, Hasin DS, Grant BF, et al. Suicidal ideation and suicide attempts in the United States: 1991-1992 and 2001-2002. Mol Psychiatry. 2010;15:250–259.

3. Scheer V, Blanco C, Olfson M, Lemogne C, Airagnes G, Peyre H, et al. A comprehensive model of predictors of suicide attempt in individuals with panic disorder: Results from a national 3-year prospective study. Gen Hosp Psychiatry. 2020;67:127–135.

4. Olfson M, Blanco C, Wall M, Liu SM, Saha TD, Pickering RP, et al. National Trends in Suicide Attempts Among Adults in the United States. JAMA Psychiatry. 2017;74:1095–1103.

5. Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112:15078–15083.

6. Tilstra AM, Simon DH, Masters RK. Trends in 'Deaths of Despair' among Working-Aged White and Black Americans, 1990-2017. Am J Epidemiol. 2021;190:1751–1759.

7. Potash JB, Scott Kane MH, Chiu Y, Simpson SG, Dean MacKinnon MF, McInnis MG, et al. Attempted Suicide and Alcoholism in Bipolar Disorder: Clinical and Familial Relationships. Am J Psychiatry. 2000;157:12.

8. Sher L. Alcoholism and suicidal behavior: A clinical overview. Acta Psychiatr Scand. 2006;113:13–22.

9. Koller G, Preuß UW, Bottlender M, Wenzel K, Soyka M. Impulsivity and aggression as predictors of suicide attempts in alcoholics. Eur Arch Psychiatry Clin Neurosci. 2002;252:155–160.

10. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. The Lancet. 2013;382:1575–1586.

11. Modesto-Lowe V, Brooks D, Ghani M. Alcohol dependence and suicidal behavior: From research to clinical challenges. Harv Rev Psychiatry. 2006;14:241–248.

12. Shepard DS, Gurewich D, Lwin AK, Reed GA, Silverman MM. Suicide and Suicidal Attempts in the United States: Costs and Policy Implications. Suicide Life Threat Behav. 2016;46:352–362.

13. Yuodelis-Flores C, Ries RK. Addiction and suicide: A review. American Journal on Addictions. 2015;24:98–104.

14. Mullins N, Kang JE, Campos AI, Coleman JRI, Edwards AC, Galfalvy H, et al. Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biol Psychiatry. 2022;91:313–327.

15. Mullins N, Bigdeli TB, Børglum AD, Coleman JRI, Demontis D, Mehta D, et al. GWAS of suicide attempt in psychiatric disorders and association with major depression polygenic risk scores. American Journal of Psychiatry. 2019;176:651–660.

16. Levey DF, Polimanti R, Cheng Z, Zhou H, Nuñez YZ, Jain S, et al. Genetic associations with suicide attempt severity and genetic overlap with major depression. Translational Psychiatry 2019 9:1. 2019;9:1–12.

17. Kimbrel NA, Ashley-Koch AE, Qin XJ, Lindquist JH, Garrett ME, Dennis MF, et al. A genome-wide association study of suicide attempts in the million veterans program identifies evidence of pan-ancestry and ancestry-specific risk loci. Mol Psychiatry. 2022;27:2264–2272.

18. Sanchez-Roige S, Palmer AA, Fontanillas P, Elson SL, Adams MJ, Howard DM, et al. Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification

Test (AUDIT) in Two Population-Based Cohorts. American Journal of Psychiatry. 2019;176:107–118.

19. Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, et al. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019;10:1499.

20. Walters RK, Polimanti R, Johnson EOECEO, McClintick JN, Adams MJ, Adkins AE, et al. Trans-ancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. Nat Neurosci. 2018;21:1656–1669.

21. Zhou H, Sealock JM, Sanchez-Roige S, Clarke TK, Levey DF, Cheng Z, et al. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nat Neurosci. 2020. 2020. https://doi.org/10.1038/s41593-020-0643-5.

22. Richard-Devantoy S, Berlim MT, Jollant F. A meta-analysis of neuropsychological markers of vulnerability to suicidal behavior in mood disorders. Psychol Med. 2014;44:1663–1673.

23. Richard-Devantoy S, Gorwood P, Annweiler C, Olié JP, Le Gall D, Beauchet O. Suicidal behaviours in affective disorders: A deficit of cognitive inhibition? Canadian Journal of Psychiatry. 2012;57:254–262.

24. Keilp JG, Gorlyn M, Russell M, Oquendo MA, Burke AK, Harkavy-Friedman J, et al. Neuropsychological function and suicidal behavior: Attention control, memory and executive dysfunction in suicide attempt. Psychol Med. 2013;43:539–551.

25. Le Berre AP. Emotional processing and social cognition in alcohol use disorder. Neuropsychology. 2019;33:808–821.

26. Le Berre AP, Fama R, Sullivan E V. Executive Functions, Memory, and Social Cognitive Deficits and Recovery in Chronic Alcoholism: A Critical Review to Inform Future Research. Alcohol Clin Exp Res. 2017;41:1432–1443.

27. Cabé N, Laniepce A, Ritz L, Lannuzel C, Boudehent C, Vabret F, et al. Cognitive impairments in alcohol dependence: From screening to treatment improvements. Encephale. 2016;42:74–81.

28. Park SM, Lee JY, Kim YJ, Lee J-Y, Jung HY, Sohn BK, et al. Neural connectivity in Internet gaming disorder and alcohol use disorder: A resting-state EEG coherence study. Sci Rep. 2017;7:1333.

29. Cardenas VA, Price M, Fein G. EEG coherence related to fMRI resting state synchrony in long-term abstinent alcoholics. Neuroimage Clin. 2018;17:481–490.

30. Mumtaz W, Vuong PL, Xia L, Malik AS, Rashid RBA. An EEG-based machine learning method to screen alcohol use disorder. Cogn Neurodyn. 2017;11:161–171.

31. Kamarajan C, Ardekani BA, Pandey AK, Chorlian DB, Kinreich S, Pandey G, et al. Random forest classification of alcohol use disorder using EEG source functional connectivity, neuropsychological functioning, and impulsivity measures. Behavioral Sciences. 2020;10.

32. Leuchter AF, Cook IA, Hunter AM, Cai C, Horvath S. Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression. PLoS One. 2012;7.

33. Ehlers CL, Wills DN, Karriker-Jaffe KJ, Gilder DA, Phillips E, Bernert RA. Delta Event-Related Oscillations Are Related to a History of Extreme Binge Drinking in Adolescence and Lifetime Suicide Risk. Behavioral Sciences. 2020;10:154.

34. Bucholz KK, Cadoret R, Cloninger CR, Dinwiddie SH, Hesselbrock VM, Nurnberger JI, et al. A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. J Stud Alcohol. 1994;55:149–158.

35. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86:1119–1127.

36. Lai D, Kapoor M, Wetherill L, Schwandt M, Ramchandani VA, Goldman D, et al. Genome-wide admixture mapping of DSM-IV alcohol dependence, criterion count, and the self-rating of the effects of ethanol in African American populations. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2021;186:151–161.

37. Wang J-C, Foroud T, Hinrichs AL, Le NXH, Bertelsen S, Budde JP, et al. A genome-wide association study of alcohol-dependence symptom counts in extended pedigrees identifies C15orf53. Mol Psychiatry. 2013;18:1218–1224.

38. Baurley JW, Edlund CK, Pardamean CI, Conti D V., Bergen AW. Smokescreen: a targeted genotyping array for addiction research. BMC Genomics. 2016;17:145.

39. Delaneau O, Howie B, Cox AJ, Zagury J-F, Marchini J. Haplotype estimation using sequencing reads. Am J Hum Genet. 2013;93:687–696.

40. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48:1284–1287.

41. Wetherill L, Agrawal A, Kapoor M, Bertelsen S, Bierut LJ, Brooks A, et al. Association of substance dependence phenotypes in the COGA sample. Addiction Biology. 2015;20:617–627.

42. Meyers JL, Zhang J, Wang JC, Su J, Kuo SI, Kapoor M, et al. An endophenotype approach to the genetics of alcohol dependence: a genome wide association study of fast beta EEG in families of African ancestry. Mol Psychiatry. 2017. 2017. https://doi.org/10.1038/mp.2016.239.

43. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343–352.

44. Mills MC, Rahal C. A scientometric review of genome-wide association studies. Commun Biol. 2019;2:9.

45. Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, et al. Human Demographic History Impacts Genetic Risk Prediction across Diverse Populations. Am J Hum Genet. 2017;100:635–649.

46. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun. 2019. 2019. https://doi.org/10.1038/s41467-019-11112-0.

47. Ruan Y, Lin Y-F, Feng Y-CA, Chen C-Y, Lam M, Guo Z, et al. Improving Polygenic Prediction in Ancestrally Diverse Populations. Nat Genet. 2022. 2022. https://doi.org/10.1038/s41588-022-01054-7.

48. Chorlian DB, Rangaswamy M, Porjesz B. EEG coherence: Topography and frequency structure. Exp Brain Res. 2009;198:59–83.

49. Nunez PL, Srinivasan R, Westdorp AF, Wijesinghe RS, Tucker DM, Silberstein RB, et al. EEG coherency. I: Statistics, reference electrode, volume conduction, Laplacians, cortical imaging, and interpretation at multiple scales. Electroencephalogr Clin Neurophysiol. 1997;103:499–515.

50. Muthén LK, Muthén BO. Statistical analysis with latent variables. User's Guide. 2001;4.

51. Lai D, Wetherill L, Bertelsen S, Carey CE, Kamarajan C, Kapoor M, et al. Genome-wide association studies of alcohol dependence, DSM-IV criterion count and individual criteria. Genes Brain Behav. 2019;18.

52. Chen MH, Yang Q. GWAF: An R package for genome-wide association analyses with family data. Bioinformatics. 2009;26:580–581.

53. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190–2191.

54. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.

55. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8:1–11.

56. Akimova ET, Breen R, Brazel DM, Mills MC. Gene-environment dependencies lead to collider bias in models with polygenic scores. Sci Rep. 2021;11:1–9.

57. Ripley B. Feed-forward neural networks and multinomial log-linear models. R package nnet. Version 7.3-15. 2021. 28 September 2021.

58. Davenport C, Soule SA, Armstrong DA. Protesting while black? the differential policing of american activism, 1960 to 1990. Am Sociol Rev. 2011;76:152–178.

59. Cameron CA, Gelbach JB, Miller DL. Robust inference with multiway clustering. Journal of Business and Economic Statistics. 2011;29:238–249.

60. Pandey G, Seay MJ, Meyers JL, Chorlian DB, Pandey AK, Kamarajan C, et al. Density and Dichotomous Family History Measures of Alcohol Use Disorder as Predictors of Behavioral and Neural Phenotypes: A Comparative Study Across Gender and Race/Ethnicity. Alcohol Clin Exp Res. 2020;44:697–710.

61. Grant BF, Saha TD, June Ruan W, Goldstein RB, Patricia Chou S, Jung J, et al. Epidemiology of DSM-5 drug use disorder results from the national epidemiologic survey on alcohol and related conditions-III. JAMA Psychiatry. 2016;73:39–47.

62. Magnani D, Morlé L, Hasenpusch-Theil K, Paschaki M, Jacoby M, Schurmans S, et al. The ciliogenic transcription factor Rfx3 is required for the formation of the thalamocortical tract by regulating the patterning of prethalamus and ventral telencephalon. Hum Mol Genet. 2015;24:2578–2593.

63. Benadiba C, Magnani D, Niquille M, Morlé L, Valloton D, Nawabi H, et al. The Ciliogenic Transcription Factor RFX3 regulates early midline distribution of guidepost neurons required for corpus callosum development. PLoS Genet. 2012;8.

64. Stein MB, McCarthy MJ, Chen CY, Jain S, Gelernter J, He F, et al. Genome-wide analysis of insomnia disorder. Mol Psychiatry. 2018;23:2238–2250.

65. Hammerschlag AR, Stringer S, de Leeuw CA, Sniekers S, Taskesen E, Watanabe K, et al. Genome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits. Nat Genet. 2017;49:1584–1592.

66. Ni H, Xu M, Zhan G-L, Fan Y, Zhou H, Jiang H-Y, et al. The GWAS Risk Genes for Depression May Be Actively Involved in Alzheimer's Disease. Journal of Alzheimer's Disease. 2018;64:1149–1161.

67. Fabbri C, Kasper S, Kautzky A, Bartova L, Dold M, Zohar J, et al. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. British Journal of Psychiatry. 2019;214:36–41.

68. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51:237–244.

69. Hasan S, Robbani SM, Afroze T, Ahsan G, Hossain MM. Identifying Changes to RNA Editome in Major Depressive Disorder. BioRxiv. 2018:419309.

70. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–681.

71. Hyde CL, Nagle MW, Tian C, Chen X, Paciga SA, Wendland JR, et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nat Genet. 2016;48:1031–1036.

72. Yang Y, Wang L, Li L, Li W, Zhang Y, Chang H, et al. Genetic association and meta-analysis of a schizophrenia GWAS variant rs10489202 in East Asian populations. Transl Psychiatry. 2018;8.

73. Shi Y, Li Z, Xu Q, Wang T, Li T, Shen J, et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet. 2011;43:1224–1227.

74. Dudbridge F. Power and Predictive Accuracy of Polygenic Risk Scores. PLoS Genet. 2013;9:e1003348.

75. Leuchter AF, Cook IA, Hunter AM, Cai C, Horvath S. Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression. PLoS One. 2012;7:e32508.

76. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51:584–591.

Figure Captions

Figure 1: Gene based results for genome-wide association of those with AD who have attempted suicide in EUR (N = 3,270) and AFR COGA Participants (N = 798).

Gene based results for genome-wide association study findings comparing COGA participants with DSM-IV AD who have attempted suicide compared to those with AD who have not attempted suicide in (A) European ancestries (N=3270) and (B) Admixed African American ancestries (N=798). The dashed red line indicates the statistical significance threshold of $p < 4.05 \times 10^{-6}$ (calculated based on a Bonferroni correction for 12,337 genes tested) in EUR ancestries and threshold of $p < 3.31 \times 10^{-6}$ (calculated based on a Bonferroni correction for 15,082 genes tested) in AFR ancestries.

Figure 2: Polygenic Scores for AUD, DEP and SUI across those who have and have not reported a suicide attempt

Panel A presents odds ratios (OR) for AUD, DEP, and SUI PGSs from logistic regression models in persons with AD who had and had not attempted suicide. Panel B presents OR from multinomial logistic models (no AD, no suicide attempt as reference group). All models include cohort, sex, PC1-PC3, array, and site as covariates. SEs adjusted for familial clustering using cluster-robust standard errors. AFR = African Ancestries, EUR = European Ancestries, AUD = alcohol use disorder polygenic score, DEP = depression polygenic score, = SUI suicide attempt polygenic score, SA- = no lifetime suicide attempt, AD- = does not meet criteria for alcohol dependence, SA+ = lifetime suicide attempt, AD+ = meets criteria for alcohol dependence.

A

B

Figure 1: Gene based results for genome-wide association of those with AD who have attempted suicide in EUR (N = 3,270) and AFR COGA Participants (N = 798).

Figure 2: Polygenic Scores for AUD, DEP and SUI across those who have and have not reported a suicide attempt

Table 1. Sociodemographic Indicators, Trauma Exposure, Psychiatric and Substance Use Disorders in COGA Participants with Alcohol Dependence (N = 4,068)

	No Suicide Attempt (N = 3,138)	Suicide Attempt (N = 930)
Socio-demographics		
Female (%)	31.8%	53.1%*
Black or African American (%)	20.5%	16.7%
Hispanic (%)	6.2%	8.5%
Mean age at last interview (SD)	39.9 (11.9)	38.2 (10.5)
Suicide related behavior		
Suicidal Ideation (%)	46.8%	97.6%*
Alcohol Use Disorder Indicators		
Maximum # of AD criteria endorsed	5.1 (1.7)	5.6 (1.6)*
Maximum # drinks consumed/24hrs	28.8 (18.6)	34.2 (22.1)*
Mean age of AD onset (SD)	24.1 (8.4)	22.5 (7.3)*
Mean age of first whole drink (SD)	15.0 (2.3)	13.7 (2.4)*
Ratio of first-degree relatives with AD	0.4	0.5*
Trauma Exposure		
Sexual Assaultive Trauma (%)	23.0%	45.1*
Assaultive Trauma (%)	34.5%	53.8*
Non-Assaultive Trauma (%)	59.3%	71.2*
DSM-IV Psychiatric Comorbidities		
Major Depression (%)	9.6%	56.0%*
Panic disorder (%)	2.5%	5.3%
Obsessive Compulsive Disorder (%)	0.7%	5.3%
Social phobia (%)	5.3%	10.6%
Agoraphobia (%)	3.5%	10.8%
Post-Traumatic Stress Disorder (%)	6.3%	19.1%*
Anorexia Nervosa (%)	0.0%	2.1%
Bulimia (%)	3.4%	15.4%
Mania (%)	0.5%	2.1%
Attention-Deficit Hyperactive Disorder (%)	7.1%	4.3%
Conduct Disorder (%)	31.3%	31.9%
Antisocial Personality Disorder (%)	22.6%	30.9%
Nicotine Dependence (%)	53.8%	73.7%*
Cannabis Dependence (%)	34.7%	28.7%
Cocaine Dependence (%)	29.2%	35.1%*
Stimulant Dependence (%)	13.4%	18.1%*
Sedative Dependence (%)	5.3%	13.7%*
Opioid Dependence (%)	10.4%	12.6%

* $p < .05$